The business combination will develop solutions across the care continuum by bringing together Hyperfine and Liminal, two companies with the potential to drive a transformative shift in MR imaging, brain-sensing capabilities, and robotic guided inter
This will accelerate the development of an open proteomics platform to democratize single molecule analysis — empowering innovators and transforming the future of healthcare through better diagnostics to improve the efficacy of drug treatments
The transaction will merge Quantum-Si’s revolutionary, end-to-end proteomics solution, and HighCape Capital Acquisition Corp., a healthcare-focused SPAC sponsored by leading healthcare growth equity investment firm HighCape Capital LP.
This will fuel further adoption and help accelerate Butterfly’s current and future pipeline of innovative technologies, which have the potential to transform health care delivery and drive a direct impact for patients.
Detect is working on making more accurate routine Covid-19 testing a reality.
Hyperfine received 510(k) clearance from the US FDA for its deep-learning image analysis software.
The merger will accelerate the commercialization of Butterfly’s innovative handheld ultrasound, the Butterfly iQ. NYSE Ticker will officially become “BFLY” in Q1 2021
The New York Times describes how the Butterfly iQ is used in African villages like Bushoro, Uganda.
President Obama has named Dr. Jonathan Rothberg, founder of medical device incubator 4Catalyzer, as a recipient of the National Medal of Technology and Innovation. The award is the nation’s highest honor for technical achievement and innovation.
Nevada Sanchez, a co-founder at Butterfly Network (a 4Catalyzer company), has been honored as one of Forbes 30 under 30 for 2015.